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The treatment of metastatic prostate cancer patients refractory to androgen withdrawal and docetaxel therapy is currently
discouraging and new therapeutic approaches are vastly needed. Here, we report a long-term remission over one year in a
68-year-old patient with metastatic docetaxel-refractory prostate cancer employing low-dose trofosfamide. The patient suﬀered
from distant failure with several bone lesions and lymph node metastases depicted by a (11) C-Choline positron emission
tomography/computerized tomography (PET/CT). After initiation of trofosfamide 100mg taken orally once a day we observed a
steadily decreasing PSA value from initial 46.6 down to 2.1µg/l. The Choline-PET/CT was repeated after 10 months of continuous
therapy and demonstrated a partial remission of the bone lesions and a regression of all involved lymph nodes but one. Taken
together we found an astonishing and durable activity of the alkylating agent trofosfamide given in a metronomic fashion. We rate
t h es i d ee ﬀects as low and state an excellent therapeutic ratio of this drug in our patient.
1.Introduction
In hormone-refractory prostate cancer (HRPC) the treat-
ment of choice is chemotherapy with docetaxel plus pred-
nisone since this combination has shown a survival ben-
eﬁt in a large phase III trial. However, this therapy is
often associated with considerable toxicity. After docetaxel
failure currently no standard of care exists. In such a
palliative setting a treatment strategy is highly desirable,
which provides antitumoral activity without causing a
signiﬁcant amount of toxicity. In the last years the concept
of metronomic chemotherapy has emerged, which fulﬁlls
these requirements [1]. Metronomic chemotherapy means
the continuous administration of relatively low, nontoxic
doses of chemotherapeutic drugs mainly aiming on the
prevention of tumor angiogenesis. Alkylating agents like
cyclophosphamide and the more lipophilic trofosfamide
have been employed in this therapeutic setting and have led
tosurprisinglypotenttumoreﬀectsinawiderangeoftumors
[2, 3]. Here we report on patient with advanced prostate
cancer, who achieved a long-term remission after therapy
with low-dose trofosfamide. The present case demonstrates
the value of the metronomic concept in patients with
advanced HRPC.
2. Case Presentation
In this paper, we describe a long-term partial remission over
one yearofa68-year-old mantreatedwithoraltrofosfamide.
Diagnosis was established in January 2005 (pT3b pN1 M0
V1 L1, Gleason Score 9) and prostatectomy, extended ﬁeld
radiation, and orchiectomy were performed. After complete2 Case Reports in Medicine
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Figure 1: PSA course during trofosfamide treatment.
androgen depletion with bicalutamide (casodex) the patient
relapsed one year later. This patient showed multiple bone
lesions and lymph node metastases and was refractory to
standard dose docetaxel treatment (75mg/m2, qd21, six
cycles). After the beginning of docetaxel application PSA was
initially declining then increased again. Moreover, after six
cycles of docetaxel the patient developed a polyneuropathy
grade II. Directly after docetaxel treatment the PSA value
rose continuously and antihormonal treatment was ongoing.
Before and after treatment with docetaxel, alkaline phos-
phatase, haemoglobin, and lactate dehydrogenase were in
normal ranges. Intravenous bisphosphonate treatment with
zoledronic acid (4mg, every four weeks) was already started
one year before the initiation of trofosfamide therapy.
Trofosfamide was started in August 2007 with the stan-
dard dose of 150mg orally per day in an outpatient setting.
D u et om o d e r a t es i d ee ﬀects like a facial rash and paresthesia
of the lower legs, the dose was reduced to 100mg per day
after 4 weeks of treatment. Both side eﬀects are not typical
for trofosfamide. Probably the neurological symptoms can
be explained with preexisting polyneuropathy which already
developed during the docetaxel treatment. The neuropathy
was under excellent control by a treatment with pregabalin.
After treatment the PSA value continuously decreased from
46.6 to 2.1µg/l. Figure 1 illustrates the PSA course before
and after a one-year treatment period with trofosfamide.
No signiﬁcant treatment-related toxicity was detected after
the dose reduction to 100mg and the drug was tolerated
well (Karnofsky index 100% during the whole treatment).
(11)C-cholinepositronemissiontomography/computerized
tomography(PET/CT)wasperformedbeforeand10months
after start of treatment with trofosfamide. In the choline-
PET/CT a partial remission of bone lesions and a regression
of all but one involved lymph nodes were demonstrated.
Figures 2(a) and 2(b) show the remission of systemic
metastases detected by choline-PET/CT after a 10-month
treatment with trofosfamide.
3. Discussion
Prostate cancer is a common cause of death in men
and remains incurable in the metastatic setting. Standard
treatment for metastatic disease contains androgen abla-
tion followed by chemotherapy, if hormone-refractoriness
occurs. Chemotherapy has evolved over time since the 1960s
and several agents are currently approved like estramus-
tine, mitoxantrone, and docetaxel. Two important clinical
trials (TAX 327 and SWOG 99-16) showed for the ﬁrst
time a survival beneﬁt in men with metastatic HRPC. In
particular, docetaxel-based chemotherapy demonstrated a
median improvement in overall survival of 2.5 months
as compared with mitoxantrone and prednisone (MP) in
metastatic HRPC [4]. If a patient is refractory to doc-
etaxel, he can proceed to investigational therapy. In this
situation second-line chemotherapy has not been exten-
sively studied, but generally it leads to a short median
progression-free survival of just a few months. Rosen-
berg et al. demonstrated a modest activity of second-line
chemotherapy(phase2studyofixabepiloneormitoxantrone
and prednisone) with no advantage for any treatment arm
[5].
A promising new treatment strategy in prostate cancer
is the targeting of tumor angiogenesis. Antiangiogenic
strategies seem to be rationale in HRPC, because microvessel
density is an independent prognostic factor for progression
and survival in clinically localized prostate cancer. More-
over, tumor angiogenesis correlates with metastases and
progression also in advanced HRPC [6, 7]. Several new
drugs, which have antiangiogenic activity like bevacizumab,
tyrosine kinase inhibitors like sorafenib or sunitinib, and
mTor inhibitors like everolimus are under clinical investiga-
tion. These targeted agents either neutralize VEGF directly
or abrogate downstream pathways of growth receptors like
VEGFR or PDGFR.
Beside targeted drugs, thalidomide and low-dose trofos-
famide are also eﬀective through an antiangiogenic manner;
however, they employ a diﬀerent mode of action [8].
In a study including twenty patients with a progression
on androgen ablation and/or estramustine treated with
trofosfamide per os (150mg/day) the authors concluded that
trofosfamide has activity in hormone-refractory advanced
prostate cancer, 5 patients (27%) had a decline of the PSA
levels [9]. In contrast to a cyclic schedule, where the dosage
intervals lead to peak levels of the cytostatic drugs followedCase Reports in Medicine 3
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Figure 2: (a) and (b) show exemplarily the regression of a lymph node metastasis, demonstrated by choline-PET-CT before and 10 months
after treatment with trofosfamide.
by subtherapeutic levels, continuous application of the active
drug maintains a more constant drug level. As a conse-
quence, metronomic scheduling of trofosfamide prevented
the mobilization of circulating endothelial progenitor cells
(EPCs). This was in contrast to conventional dose-dense
chemotherapy which promoted a release of EPCs through a
rebound mechanism [10]. Although we have no transitional
data to support the hypothesis in this case, one might spec-
ulate that such a prevention of EPCs release might have also
contributed to the favorable clinical course of our patient,
who received 50 mg per day less than the standard dose.
It is noteworthy that the combined use of antiangiogenic
agents and zoledronic acid seems to put the patients at
risk of a characteristical bisphosphonate-associated compli-
cation named osteonecrosis of the jaw (ONJ) [11]a n do n e
should have this complication in mind when clinical signs
occur.
4. Conclusion
Taken together, we found high activity of metronomically
administered trofosfamide in a situation beyond standard
treatment algorithms. We conclude, that low-dose trofos-
famide could be a treatment option for patients with
advanced prostate cancer, also in a docetaxel-resistant set-
ting. Since our patient improved with a lowered dose of
trofosfamide, we suggest that the optimal antiangiogenic
dose and schedule of trofosfamide in this setting has yet to
be determined.4 Case Reports in Medicine
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